MTEM Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases...

Stats
Tagesvolumen	68 803.00
Durchschnittsvolumen	64 717.00
Marktkapitalisierung	9.16M
EPS	$0 ( 2024-04-04 )
Nächstes Ertragsdatum	( $-0.780 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0330 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Biotech Target N V	Buy	250 000	Common Stock
2024-04-02	Biotech Target N V	Buy	769 334	Common Warrants (right to buy)
2024-04-02	Biotech Target N V	Buy	134 667	Prefunded Warrants (right to buy)
2024-04-02	Lalande Kevin M.	Buy	1 154 154	Warrants (Right to Buy)
2024-04-02	Lalande Kevin M.	Buy	402 077	Pre-Funded Warrants (Right to Buy)

INSIDER POWER
99.93
Last 98 transactions
Buy: 16 322 736 \| Sell: 222 785

Volumen Korrelation

Lang: 0.01 (neutral)

Kurz: -0.59 (weak negative)

Signal:(58.538) Neutral

Molecular Templates Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Molecular Templates Inc Korrelation - Währung/Rohstoff

-0.41
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.03
( neutral )

-0.19
( neutral )

Molecular Templates Inc Finanzdaten

Annual	2023
Umsatz:	$57.31M
Bruttogewinn:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2023
Umsatz:	$57.31M
Bruttogewinn:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2022
Umsatz:	$19.75M
Bruttogewinn:	$11.95M (60.51 %)
EPS:	$-24.69

FY	2021
Umsatz:	$38.70M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$1.690

Financial Reports:

No articles found.

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.